MERCK HAD THE ORIGINAL PATEN ON IVERMECTIN; MEANWHILE, MERCK ANNOUNCED ON SEPT. 1 THAT ITS COVID PILL IS MOVING ON TO A PHASE 3 CLINICAL TRIAL. THE MEDICATION, KNOWN AS MOLNUPIRAVIR, IS AN
MOLNUPIRAVIR “INHIBITS VIRAL REPLICATION,” ALAN SAYS. MEANING, IT KEEPS SARS-COV-2, THE VIRUS THAT CAUSES COVID-19, FROM REPRODUCING IN YOUR BODY AND MAKING YOU SICK. GEE THIS SOUNDS VERY FAMALIAR
